Skip to main content

Advertisement

SpringerLink
Log in

Increased levels of urokinase plasminogen activator receptor in prostate cancer cells derived from repeated metastasis

  • Free Paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

To understand alterations to the urokinase system that may occur in progressively metastatic prostate cancer cells, we assessed urokinase plasminogen activator receptor (uPAR) expression, in vitro motility towards vitronectin, urokinase plasminogen activator (uPA)-induced growth and growth factor regulation of uPAR expression in three cell lines—PC-3 and two derivatives from secondary metastases, PC-3M and PC-3MM2. DU-145 and Tsu-Pr1 cells were included for comparative purposes. uPAR expression increases with metastatic passage in these cell lines and accompanies increased growth and motility responses in the presence of uPA. Growth factors TGFβ1 and IGF-1 induce uPAR in all three prostate cancer lines; however, PC-3M and PC-3MM2 cells also respond to bFGF. Of the cell lines tested, PC-3MM2 most uniformly respond to added TGFβ1, IGF-1 and bFGF. These results show that in two progressive derivatives from repeated metastasis of PC-3 cells, constitutive and growth factor-induced uPAR expression is enhanced. This increased uPAR facilitates the properties of growth and motility.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Berger D (2002) Plasmin/plasminogen system in colorectal cancer. World J Surg 26:767–771

    Article  PubMed  Google Scholar 

  2. Biliran H, Sheng S (2001) Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin. Cancer Res 61:8676–8682

    CAS  PubMed  Google Scholar 

  3. Bissell MJ, Le Beyec J, Anderson RL (2002) Prostate cancer in bone: importance of context for inhibition of matrix metalloproteinases. J Natl Cancer Inst 94:4–5

    Google Scholar 

  4. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ (2000) Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31:578-83

    CAS  PubMed  Google Scholar 

  5. Delworth MG, Nishioka K, Pettaway CA, Gutman M, Killion JJ, Von Eschenbach AC, Fidler IJ (1995) Systemic administration of 4-amidinoindanon-1-(2′-amidino)-hydrazone, a new inhibitor of S-adenosylmethionine decarboxylase, produces cytostasis of human prostate cancer in athymic nude mice. Int J Oncol 6:293–299

    CAS  Google Scholar 

  6. Evans CP, Elfman F, Parangi S, Conn M, Cunha G, Shuman MA (1997) Inhibition of prostate cancer neovascularization and growth by urokinase-plasminogen activator receptor blockade. Cancer Res 57:3594–3599

    CAS  PubMed  Google Scholar 

  7. Festuccia C, Dolo V, Guerra F, Violini S, Muzi P, Pavan A, Bologna M (1998) Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells. Clin Exp Metastasis 16:513–528

    Article  CAS  PubMed  Google Scholar 

  8. Greene GF, Kitadal Y, Pettaway CA, Von Eschenbach AC, Bucana CD, Fidler IJ (1997) Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique. Am J Pathol 150:1571–1582

    CAS  PubMed  Google Scholar 

  9. Hollas W, Hoosein N, Chung LWK, Mazar A, Henkin J, Kariko K, Barnathan ES, Boyd D (1992) Expression of urokinase and its receptor in invasive and non-invasive prostate cancer cell lines. Thrombo Haemost 68:662–666

    CAS  Google Scholar 

  10. Hoyer-Hansen G, Behrendt N, Ploug M, Dano K, Preissner KT (1997) The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction. FEBS Lett 420:79–85

    Article  CAS  PubMed  Google Scholar 

  11. Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S (1999) Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate 39:123–129

    Article  CAS  PubMed  Google Scholar 

  12. Pettaway CA, Pathak S, Greene G, Ramirez E, Wilson MR, Killion JJ, Fidler IJ (1996) Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin Cancer Res 2:1627–1636

    CAS  PubMed  Google Scholar 

  13. Rabbani SA, Gladu J (2002) Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo. Cancer Res 62:2390–23970

    Google Scholar 

  14. Rabbani SA, Xing RH (1998) Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies. Int J Oncol 12:911–2

    CAS  PubMed  Google Scholar 

  15. Sehgal I, Forbes K, Webb M (2003) Reduced expression of MMPs, plasminogen activators and TIMPS in prostate cancer cells during repeated metastatic selection. Anticancer Res 23: (in press)

  16. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, Von Eschenbach AC, Chung LW (1994) Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 54:2577–81

    CAS  PubMed  Google Scholar 

  17. Thompson TC, Timme TL, Sehgal I (1998) Oncogenes, growth factors, and hormones in prostate cancer. In: Dickson RB, Salomon DS (eds) Hormones and growth factors in development and neoplasia. Wiley-Liss, New York, pp 327–359

  18. Varkarakis MJ, Winterberger AR, Gaeta J, Moore RH, Murphy GP (1974) Lung metastases in prostate carcinoma. Urology 3:447–452

    CAS  PubMed  Google Scholar 

  19. Von Bokhoven A, Garcia MV, Korch C, Miller, GJ (2001) TSU-Pr1 and JCA-1 cells are derivatives of T24 bladder carcinoma cells and are not of prostatic origin. Cancer Res61:6340–6344

    Google Scholar 

  20. Webb CP, Hose CD, Koochekpour S, Jeffers M, Oskarsson M, Sausville E, Monks A, Vande Woude GF (2000) The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network. Cancer Res 60:342-349

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by funds from the NCRR (P20 RR15566), NCI (R15 CA-82139), the Fraternal Order of Eagles and the Department of Defense (PC991403) to I.S.

Author information

Authors and Affiliations

  1. Center for Protease Research, North Dakota State University, Fargo, ND 50105, USA

    Katie Forbes & Karin Gillette

  2. USDA Laboratory, North Dakota State University, Fargo, ND 58105, USA

    Laura A. Kelley

  3. School of Veterinary Medicine, Comparative Biomedical Sciences, Louisiana State University, Skip Bertman Drive, Baton Rouge, LA 70809, USA

    Inder Sehgal

Authors
  1. Katie Forbes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karin Gillette
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Laura A. Kelley
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Inder Sehgal
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Forbes, K., Gillette, K., Kelley, L.A. et al. Increased levels of urokinase plasminogen activator receptor in prostate cancer cells derived from repeated metastasis. World J Urol 22, 67–71 (2004). https://doi.org/10.1007/s00345-003-0395-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-003-0395-3

Keywords

Search

Navigation